Coverage
Filings
Genmab A/S announced encouraging results from its Phase 1/2 RAINFOL-01 trial for rinatabart sesutecan (Rina-S), an investigational antibody-drug conjugate (ADC), in heavily pretreated patients with advanced endometrial cancer.
| 14 May 2025 |
| Transactions in Connection with Share Buy-back Program | 12 May 2025 |
| Genmab Announces Financial Results for the First Quarter of 2024 | 8 May 2025 |
| Transactions in Connection with Share Buy-back Program | 5 May 2025 |
| Transactions in Connection with Share Buy-back Program | 28 Apr 2025 |